Medical TPE Indications and ASFA Categories

What this means

The American Society for Apheresis (ASFA) publishes the Journal of Clinical Apheresis special issue that rates therapeutic apheresis in human disease. The ninth edition (2023) includes 91 fact sheets and 166 graded, categorized indications. Each sheet names a disease or condition, the apheresis procedure (often TPE), a category, and a GRADE-style recommendation. That framework is how hospitals decide whether TPE is first-line, second-line, experimental-in-practice, or should be avoided.

Category I means apheresis is accepted as first-line, either alone or with other treatments. Category II means second-line. Category III means the optimum role is not established; individualized decisions apply. Category IV means evidence suggests apheresis is ineffective or harmful for that indication. These labels attach to a specific clinical context (for example, acute MG versus some other MG setting), not to a machine brand or a clinic’s cash menu.

Wellness longevity is not an ASFA indication. Elective TPE sold to slow aging sits outside Categories I–IV as they are used in standard practice. TPE remains a hospital or specialty procedure. Infection, clotting, hypocalcemia, and access complications still apply when the category is I—and they apply even more clearly when there is no category at all.

What the evidence shows

ASFA’s own announcement of the ninth edition notes new fact sheets (including Alzheimer’s disease among others), new indications on existing sheets, and category changes. That is a living medical catalog, not a consumer ranking of anti-aging spas. Presence of an Alzheimer’s fact sheet does not mean asymptomatic aging is Category I TPE. It means specialists reviewed a defined disease context.

Examples patients actually meet: NHLBI describes hospital TPE for acquired TTP, a classic first-line apheresis use. AAN recommends plasma exchange in specified GBS windows. AAN also states plasma exchange should not be offered for chronic or secondary progressive MS—language that aligns with a Category IV-type “do not use” logic even though AAN and ASFA are separate documents. Hyperviscosity from a paraprotein is treated as urgent medical TPE, not a membership series.

ICU reviews summarize how TPE is actually delivered: access, citrate or heparin, albumin versus plasma, and complication rates. Those papers assume a disease indication. They do not provide a Category I for biological-age clocks. Small longevity trials and mouse plasma-dilution studies are research. They have not rewritten ASFA’s clinical grid into preventive care.

ASFA also publishes separate operational guidance: therapeutic apheresis should be overseen by a qualified physician, documented in the medical record, and performed by staff trained for sick patients rather than for donor collections alone. That is part of the evidence environment too. A Category I sticker on a slide does not replace privileges, blood-bank support, or a note that names volume, fluid, and stop rules. If a clinic cites the ninth edition but cannot show how it documents a procedure, the citation is decorative.

Common myths

Myth: If TPE is Category I for one disease, it is Category I for aging. Fact: Categories are indication-specific. TTP is not longevity.

Myth: Category III means “worth trying if you can pay.” Fact: Category III means uncertainty. It is a prompt for shared decision-making in a disease, not a coupon.

Myth: Category IV is outdated negativity. Fact: Category IV exists to stop ineffective or harmful use. AAN’s progressive-MS finding is a cautionary parallel: more apheresis is not automatically better.

Myth: ASFA patient sheets endorse boutique TPE. Fact: Patient information describes medical plasma exchange, photopheresis, and related procedures. It is education for people undergoing treatment, not a wellness catalog.

How clinics use it

Hospital apheresis services use ASFA sheets in consult notes: indication, category, grade, replacement fluid, number of sessions, and stop rules. ASFA also publishes guidance that therapeutic apheresis should be overseen by a qualified physician and performed by specially trained staff, because patients have diseases that the procedure can worsen. Donor-center training is not sufficient.

Neurology and hematology clinics refer into those services. They do not usually run cash longevity packages. When a longevity clinic cites “ASFA guidelines” to sell elective TPE, ask which fact sheet, which category, and which grade. If the answer is a blog or a vague “it’s used in hospitals,” they are borrowing authority without an indication.

Research protocols may study TPE in aging. That requires IRB oversight, inclusion criteria, and harm monitoring—not a menu. Alzheimer’s-related apheresis, if considered, belongs in neurology and trial settings, not as a birthday gift exchange.

Practical takeaway

Ask three questions: What disease context is this? What ASFA category and grade apply? What replacement fluid and access plan match that sheet? If staff cannot answer, you are not receiving guideline-directed TPE.

Treat Category I–II medical indications in hospitals or accredited apheresis programs with emergency coverage. Treat Category III as uncertainty, not as marketing. Treat Category IV as a stop sign. Treat longevity TPE as uncategorized speculation with the same infection, clotting, hypocalcemia, and line risks as medical TPE.

ASFA categories exist to ration a scarce, invasive procedure toward diseases where evidence supports it. They are not a ladder you climb by buying more sessions. Keep NHLBI- and AAN-aligned emergencies in specialty care. Keep aging claims in the research bin until categories say otherwise—which, for wellness longevity, they do not.

Bring a one-page summary to any second opinion: disease name, indication wording from the fact sheet, category, planned number of exchanges, replacement fluid, and the complication plan for infection, clotting, and hypocalcemia. If a longevity clinic cannot fill those blanks, you are not looking at medical TPE. You are looking at an extracorporeal product using ASFA’s reputation. Decline that substitution.